Urologic Oncology-seminars and Original Investigations最新文献

{"title":"LncRNA NPSR1-AS1 affects the malignant biological behavior of bladder cancer through miR-199a-3p and the clinical value of urine-derived lncRNA NPSR1-AS1","authors":"Weijing He M.D. ,&nbsp;Yong Wen M.D. ,&nbsp;Huiling Qin M.D.","doi":"10.1016/j.urolonc.2025.12.016","DOIUrl":"10.1016/j.urolonc.2025.12.016","url":null,"abstract":"<div><h3>Background</h3><div>The alteration of long noncoding RNA (lncRNA) expression is significantly associated with the occurrence and progression of various human tumors.</div></div><div><h3>Aim</h3><div>To explore the possible mechanism by which lncRNA NPSR1-AS1 affects bladder cancer, as well as its diagnostic and prognostic value.</div></div><div><h3>Material and methods</h3><div>The data related to bladder cancer were mined from the GEO database. RT-qPCR was used to determine the expression of lncRNA NPSR1-AS1 and miR-199a-3p in BCa tissues, cell lines and urine. Cell proliferation, migration and apoptosis and other cell functions were tested in UMUC3, T24 and cells. The interactions between molecules were studied using the luciferase reporter gene, RIP and Spearman correlation analysis. ROC, K-M and COX regression analyses were used to evaluate the clinical value of lncRNA NPSR1-AS1.</div></div><div><h3>Results</h3><div>The lncRNA NPSR1-AS1 was expressed at higher levels in BCa tissue cell lines and urine, while miR-199a-3p expression of was decreased. The lncRNA NPSR1-AS1 affected the malignant biological behavior of BCa by sponging miR-199a-3p. Cell function experiments demonstrated that silencing lncRNA NPSR1-AS1 could inhibit the proliferation, migration and apoptosis of UMUC3, T24 and RT4 cells, while the inhibition of miR-199a-3p reversed this effect. Clinically, lncRNA NPSR1-AS1 may serve as a diagnostic and prognostic marker for BCa.</div></div><div><h3>Conclusion</h3><div>LncRNA NPSR1-AS1 targets miR-199a-3p and affects the progression of BCa. Moreover, it can serve as a biomarker for BCa.</div></div>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":"44 4","pages":"Article 110980"},"PeriodicalIF":2.3,"publicationDate":"2026-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146012401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cover 2 - Masthead","authors":"","doi":"10.1016/S1078-1439(25)00505-8","DOIUrl":"10.1016/S1078-1439(25)00505-8","url":null,"abstract":"","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":"44 2","pages":"Page IFC"},"PeriodicalIF":2.3,"publicationDate":"2026-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145986753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High AST and the presence of liver metastases may guide for the need for FDG PET in advanced prostate cancer patients","authors":"Tugce Telli M.D., F.E.B.N.M. ,&nbsp;Murat Tuncel M.D. ,&nbsp;Erdem Karabulut Ph.D. ,&nbsp;Sercan Aksoy M.D. ,&nbsp;Mustafa Erman M.D. ,&nbsp;Bulent Akdogan M.D. ,&nbsp;Meltem Caglar M.D.","doi":"10.1016/j.urolonc.2025.12.010","DOIUrl":"10.1016/j.urolonc.2025.12.010","url":null,"abstract":"<div><h3>Objective</h3><div>[68Ga]/[18F] labeled Prostate Specific Membrane Antigen (PSMA) is the radiotracer of choice for imaging localized and metastatic prostate cancer with high sensitivity and specificity. On the other hand, 2-[¹⁸F]fluoro-D-glucose (FDG) Positron Emission Tomograpy/Computed Tomography (PET/CT) may help to evaluate the tumor heterogeneity in patients with metastatic castration-resistant prostate cancer (mCRPC) and determine treatment eligibility for Prostate Specific Membrane Antigen (PSMA) targeted radioligand therapy (PSMA-RLT) . The aim of the study is to evaluate the biochemical and clinical parameters which can predict the presence of FDG-PSMA discordant disease.</div></div><div><h3>Material and Methods</h3><div>A total of 70 advanced mCRPC patients who underwent [⁶⁸Ga]Ga-PSMA-11 PET and FDG PET/CT between August 2016 and June 2021 were retrospectively analyzed. Inter-tumoral heterogeneity was both visually and semi-quantitatively evaluated. Baseline clinical, laboratory and PSMA PET/CT related semi-quantitative parameters were analyzed to predict FDG discordant disease with logistic regression analysis.</div></div><div><h3>Results</h3><div>29/70 (41.4%) of the patients had FDG-PSMA discordant disease. Overall 427 mismatch lesions (FDG+PSMA-) were detected: the majority of these lesions were in the bones (<em>n</em> = 236, 55.2%), lymph nodes (<em>n</em> = 95, 22.2%), and visceral organs (<em>n</em> = 88, 20.6%). Most significant parameters to predict FDG-PSMA discordant disease were liver metastases (HR= 26.5, 95%CI 2.3-302.9, <em>P</em> = 0.008) and serum AST (HR= 1.15, 95%CI 1.04-1.26, <em>P</em> = 0.007).</div></div><div><h3>Conclusion</h3><div>The presence of liver metastases and elevated AST may be easily used in clinical practice to predict FDG-PSMA discordant disease.</div></div>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":"44 4","pages":"Article 110974"},"PeriodicalIF":2.3,"publicationDate":"2026-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145982027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world treatment patterns, recurrence, and overall survival of patients with muscle-invasive bladder cancer undergoing radical cystectomy in U.S. oncology practice","authors":"Patrick Squires Pharm.D., Ph.D. ,&nbsp;Francesca Coutinho M.B.B.S., M.P.H. ,&nbsp;Jon G. Tepsick M.S. ,&nbsp;Aljosja Rogiers M.D., Ph.D. ,&nbsp;Chethan Ramamurthy M.D. ,&nbsp;Haojie Li M.D., Ph.D. ,&nbsp;Todd M. Morgan M.D.","doi":"10.1016/j.urolonc.2025.12.018","DOIUrl":"10.1016/j.urolonc.2025.12.018","url":null,"abstract":"<div><h3>Background</h3><div>The most common treatment for muscle-invasive bladder cancer (MIBC) is radical cystectomy (RC), typically combined with neoadjuvant and/or adjuvant therapy. This study aimed to describe patient characteristics, treatment patterns, recurrence, and overall survival (OS) among a contemporary cohort of patients with MIBC who underwent RC.</div></div><div><h3>Methods</h3><div>This retrospective study included adult patients with MIBC (T2-T4aN0M0/T1-T4aN1M0) who underwent RC between January 1, 2008 and July 31, 2023 and were captured in the U.S. ConcertAI Patient360™ Bladder Cancer electronic medical record database. Index date was defined as the date of RC. Recurrence (first evidence of disease following RC) and OS were analyzed using Kaplan-Meier methods and stratified by disease stage and treatment received. The association of recurrence with OS was assessed using Cox regression.</div></div><div><h3>Results</h3><div>A total of 783 RC-treated MIBC patients were included (median age 68 years; male 78.8%; White 87.6%; de novo MIBC 77.1%; pure urothelial histology 76.6%), with a median follow-up of 26.2 months. Neoadjuvant therapy use increased from 30.3% in 2011–2013 to 67.9% in 2020–2022. Among patients who received neoadjuvant therapy, 26.3% achieved pathological complete response (pT0N0) at RC. The 5-year recurrence and OS rates were 45.2% and 48.2%, respectively, varying by stage and treatments received. Mortality was 4.4 times higher [95% CI: 3.5, 5.6] among patients with recurrence compared with those without.</div></div><div><h3>Conclusion</h3><div>Despite increased utilization of perioperative therapy over the past 2 decades, MIBC patients undergoing RC continue to experience high rates of disease recurrence, which are associated with increased mortality.</div></div>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":"44 3","pages":"Article 110982"},"PeriodicalIF":2.3,"publicationDate":"2026-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145979865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microbiome-linked transcriptomic signatures in NMIBC: Toward personalized uro-oncology","authors":"Manoj Das MBBS, MS, MCh ,&nbsp;Shree Rath MBBS ,&nbsp;Rohith Gorepatti MBBS, MS, MCh ,&nbsp;Rishikesh Dash MSc ,&nbsp;Abhishek Akella MBBS ,&nbsp;Abhay Singh Gaur MBBS, MS, MCh ,&nbsp;Giriprasad Venugopal MSc, PhD ,&nbsp;Zaiba Hasan Khan MSc, PhD ,&nbsp;Balamurugan Ramadass MSc (Med), PhD ,&nbsp;Prasant Nayak MBBS, MS, MCh","doi":"10.1016/j.urolonc.2025.12.013","DOIUrl":"10.1016/j.urolonc.2025.12.013","url":null,"abstract":"<div><h3>Background</h3><div>Nonmuscle Invasive Bladder Cancer (NMIBC) is a prevalent malignancy marked by high recurrence and progression rates. Emerging evidence suggests that demographic and environmental factors may alter the bladder’s native oncobiome, influencing tumor behavior. This exploratory pilot study examined whether paired tumor and adjacent normal bladder mucosa exhibit distinct host transcriptomic and microbial signatures that may illuminate early tumor–microbiome interactions in NMIBC.</div></div><div><h3>Methods</h3><div>A meta-transcriptomic analysis was conducted on paired tumor and adjacent normal bladder mucosa from 6 NMIBC patients. Shotgun RNA sequencing was used to profile differential gene expression and microbial composition. Functional annotation and correlation analyses were performed to explore gene–microbe interactions.</div></div><div><h3>Results</h3><div>Fifty-seven differentially expressed genes (DEGs) across 6 patients and 12 paired samples were identified, including 45 downregulated and 12 upregulated genes, primarily involved in extracellular matrix organization and structural integrity. Tumor tissues exhibited significantly reduced microbial species richness compared to the adjacent normal mucosa (<em>P</em> = 0.026). Propionibacterium acnes showed increased abundance in tumor sites (23.88%) versus the adjacent normal mucosa (13%), suggesting a protumorigenic role. Veillonella dispar and Corynebacterium durum were strongly associated with matrix-regulating genes, while Bifidobacterium longum—more abundant in the adjacent normal tissues—correlated with genes linked to extracellular homeostasis, indicating a potential protective role.</div></div><div><h3>Conclusion</h3><div>This pilot study reveals distinct transcriptomic and microbial signatures in NMIBC, highlighting the role of microbial dysbiosis, which denotes an altered microbial community; reduced diversity and shifts in key taxa relative to the adjacent bladder mucosa, in extracellular matrix remodeling and tumor progression. These host–microbe interactions may contribute to disease pathogenesis and recurrence. Further studies are warranted to elucidate the underlying mechanisms and therapeutic implications.</div></div>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":"44 3","pages":"Article 110977"},"PeriodicalIF":2.3,"publicationDate":"2026-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145979866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alopecia following single-dose postoperative intravesical gemcitabine in nonmuscle-invasive bladder cancer: A multi-institutional case series","authors":"Anosh Dadabhoy M.S. ,&nbsp;Chirag Doshi M.S. ,&nbsp;Mazyar Zahir M.D. ,&nbsp;Sanam Ladi-Seyedian M.D. ,&nbsp;Domenique Escobar M.D. ,&nbsp;Leilei Xia M.D. ,&nbsp;Anne Schuckman M.D. ,&nbsp;Christopher B. Anderson M.D. ,&nbsp;Max Kates M.D. ,&nbsp;Piyush K. Agarwal M.D. ,&nbsp;Seth P. Lerner M.D. ,&nbsp;Karim Chamie M.D. ,&nbsp;Alon Weizer M.D. ,&nbsp;Siamak Daneshmand M.D.","doi":"10.1016/j.urolonc.2025.12.020","DOIUrl":"10.1016/j.urolonc.2025.12.020","url":null,"abstract":"<div><h3>Introduction</h3><div>Single-dose intravesical gemcitabine therapy (IVGT) is a standard of care option following transurethral resection (TURBT) for low- to intermediate-risk nonmuscle invasive bladder cancer (NMIBC). The side-effect profile of IVGT has primarily focused on well-established urinary symptoms. Herein we present several cases of treatment-related alopecia following a single postoperative dose of IVGT for NMIBC.</div></div><div><h3>Methods</h3><div>Urologic oncologists from 7 high-volume bladder cancer referral centers in the United States were surveyed about incidents of alopecia, as well as the severity of hair loss, following a single postoperative dose of IVGT after TURBT- either for primary or for known NMIBC. Patients were identified either through self-reported concerns or by physician-observed alopecia during follow-up visits.</div></div><div><h3>Results</h3><div>Between January 2020 and December 2024, a total of 20 patients (6 male, 14 female) experienced hair loss, with the majority (<em>N</em> = 12, 60%) occurring within the first month post-TURBT. Thirteen of the 20 patients (65%) experienced severe alopecia. None of the patients were on medications known to cause hair loss or receiving other chemotherapy. Five patients had large resections (&gt;5 cm), ten had medium (2–5 cm), and 5 had small (&lt;2 cm) resections. Two patients had previously received IVGT without hair loss. Additionally, 4 patients had previously received intravesical <em>Bacillus</em> Calmette-Guérin (BCG), and 1 had received intravesical mitomycin C. No cases of bladder perforation were reported.</div></div><div><h3>Conclusion</h3><div>Hair loss appears to be an underreported side effect of IVGT post-TURBT. Patients should be counseled about this potential adverse event prior to treatment, and routine inquiry regarding alopecia should be considered in those undergoing IVGT post-TURBT. Prospective multicenter studies are encouraged to better evaluate the incidence and risk factors associated with this adverse event.</div></div>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":"44 3","pages":"Article 110984"},"PeriodicalIF":2.3,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145967064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of perilesional sampling in the era of targeted prostate biopsy: A scoping review","authors":"Charalampos Mavridis M.D., Ph.D. ,&nbsp;Maria Chrisoula Nakou M.D. ,&nbsp;Charalampos Mamoulakis M.D., Ph.D. ,&nbsp;Theodoros Tokas M.D., Ph.D.","doi":"10.1016/j.urolonc.2025.12.009","DOIUrl":"10.1016/j.urolonc.2025.12.009","url":null,"abstract":"<div><div>Multiparametric MRI (mpMRI) has reshaped prostate cancer diagnosis. However, Multiparametric MRI (mpMRI) often underestimates the tumor extent. Perilesional biopsy (PB) helps avoid excessive numbers of systematic biopsy (SB) cores. Nevertheless, there are concerns about the potential misses of contralateral clinically significant prostate cancer (csPCa). Despite ongoing research, a lack of high-quality studies remains. This scoping review examined the impact of PB in detecting csPCa, as well as the potential advantages and drawbacks of perilesional sampling compared to TB and systematic biopsy (SB) approaches. We conducted a PRISMA-based systematic search in Pubmed, Scopus, and WOS. We identified 77 articles, and nineteen PB studies were selected. Fourteen studies utilized an MRI-TRUS fusion software. Ten applied a sector-based or quadrant-based definition of perilesional sampling, and 8 adopted a precise mm-based definition, within a 5 mm or a ≤ 10 mm perilesional margin. We discovered a significant methodological diversity, particularly in terms of direct comparisons. Included studies recorded a wide range of csPCa detection rates (35%–99%). There were contradictory findings regarding the impact of PB on the detection rates of csPCa. Adding PB to TB decreased the detection of insignificant prostate cancer, the number of biopsy cores, and the upgrading rates in radical prostatectomy specimens. Six and 13 studies were rated as high- and moderate-risk of overall bias according to the ROBINS-I framework. Perilesional sampling during prostate biopsy is a promising yet immature strategy for detecting csPCa. The heterogeneity of methods and the lack of a standardized protocol hinder widespread adoption.</div></div>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":"44 3","pages":"Article 110973"},"PeriodicalIF":2.3,"publicationDate":"2026-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145952747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Location matters: Reduced detection of csPCa in transition zone versus peripheral zone PI-RADS lesions","authors":"Andrew M. Wood M.D. ,&nbsp;Sabrina L. Noyes B.S. ,&nbsp;Jennifer Bullen M.S. ,&nbsp;Anna Johnson M.S. ,&nbsp;Prajit Khooblall M.D. ,&nbsp;Andrew Moriarity M.D. ,&nbsp;Tarik Benidir M.D. ,&nbsp;Jane K. Nguyen M.D., Ph.D. ,&nbsp;Ruben Olivares M.D. ,&nbsp;Zeyad Schwen M.D. ,&nbsp;Samuel Haywood M.D. ,&nbsp;Eric Klein M.D. ,&nbsp;Ryan D. Ward M.D. ,&nbsp;Matthew S. Davenport M.D. ,&nbsp;Andrei S. Purysko M.D. ,&nbsp;Christopher J. Weight M.D. ,&nbsp;Brian R. Lane M.D., Ph.D.","doi":"10.1016/j.urolonc.2025.12.011","DOIUrl":"10.1016/j.urolonc.2025.12.011","url":null,"abstract":"<div><h3>Purpose</h3><div>Fusion prostate biopsy of prostate imaging report and data system lesions has become an integral part of diagnosis of prostate cancer. Though the scoring system is slightly different between peripheral zone and transition zone located lesions, a score of 4 or 5, regardless of lesion location is associated with a high or very high chance of clinically significant prostate cancer. Our goal is to examine whether lesion location impacts detection of clinically significant prostate cancer, defined as International Society of Urological Pathology grade group ≥2.</div></div><div><h3>Materials and Methods</h3><div>Multi-institutional retrospective review of patients who underwent MRI fusion biopsy at 3 tertiary care medical centers between 2017 and 2022. Lesion level review was performed to compare targeted biopsy results for PI-RADS 4 and 5 lesions located in the transition zone and peripheral zone. Primary outcome of interest was detection of clinically significant prostate cancer. Multivariable logistic regression analyses were performed to assess for predictors of clinically significant prostate cancer detection.</div></div><div><h3>Results and Conclusions</h3><div>Two thousand one hundred twenty eight lesions from 1,635 patients were included. On multivariate analysis, lesions located in the transition zone were independently associated with decreased detection of clinically significant prostate cancer (OR 0.55, <em>P</em> &lt; 0.001). Similarly, detection of grade group 3 or higher prostate cancer was also lower for lesions in the transition zone (adjusted OR: 0.37; 95% CI: 0.26–0.54; <em>P</em> &lt; 0.001). These differences have implications for further workup in patients with negative or low-grade pathology on MRI-TBx of PI-RADS 5 lesions and suggest a needs for reworking of the PI-RADS system.</div></div>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":"44 3","pages":"Article 110975"},"PeriodicalIF":2.3,"publicationDate":"2026-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145928745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of periurethral structural reinforcement technique on early urinary continence recovery following laparoscopic radical prostatectomy: A retrospective study","authors":"Chenxu Ma B.SC. ,&nbsp;Lili Chen B.SC. ,&nbsp;Yongxiang Li M.D. ,&nbsp;Liang Qiao M.D. ,&nbsp;Yadong Sun M.D.","doi":"10.1016/j.urolonc.2025.12.012","DOIUrl":"10.1016/j.urolonc.2025.12.012","url":null,"abstract":"<div><h3>Purpose</h3><div>This retrospective comparative study aims to evaluate the safety and efficacy of a novel periurethral structural reinforcement (PSR) technique for enhancing early urinary continence recovery after laparoscopic radical prostatectomy (LRP).</div></div><div><h3>Methods</h3><div>Clinical records of 140 prostate cancer patients undergoing LRP between March 2022 to August 2023 were reviewed. Participants were divided into modified (PSR) and conventional (standard anastomosis) groups. The PSR technique augments standard posterior reconstruction by incorporating circumferential support sutures, aimed at reconstructing key surgical-damaged periurethral supports. Continence status (≤1 pad/day) were analyzed at catheter removal, 1, 2 4, and 12 weeks following surgery. Operative time, complications and pathologic characteristics were compared between 2 groups.</div></div><div><h3>Results</h3><div>Baseline characteristics were comparable among 2 groups. The modified group maintained superior continence recovery at all time intervals: 16.0% vs. 0% (immediate, <em>P</em> &lt; 0.001), 20.0% vs. 6.7% (1 week, <em>P</em> = 0.018), 52.0% vs. 27.8% (4 weeks, <em>P</em> = 0.004), and 82.0% vs. 52.2% (12 weeks, <em>P</em> &lt; 0.001), respectively. Complication rates showed no significant difference (<em>P</em> &gt; 0.05).</div></div><div><h3>Conclusion</h3><div>The PSR technique is a safe and simple technique to accelerate early urinary continence recovery following LRP. Nevertheless, the generalizability of these outcomes require rigorous validation through a large-scale multicenter randomized controlled trial.</div></div>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":"44 3","pages":"Article 110976"},"PeriodicalIF":2.3,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145904052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prostate cancer deaths will decrease by 2050.","authors":"Nicholas N Brutus, Maximilian J Rabil, Isaac Y Kim","doi":"10.1016/j.urolonc.2025.12.007","DOIUrl":"https://doi.org/10.1016/j.urolonc.2025.12.007","url":null,"abstract":"","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":"110971"},"PeriodicalIF":2.3,"publicationDate":"2026-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145918502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}